Valneva and pfizer report positive phase 2 pediatric data for lyme disease vaccine candidate

Saint-herblain, france & new york--(business wire)--valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, and pfizer inc. (nyse: pfe) today reported positive phase 2 pediatric data for their lyme disease vaccine candidate, vla15. based on these new results, valneva and pfizer plan to proceed with inclusion of pediatric participants in their planned phase 3 trial. the trial will evaluate vla15 in adults and pediatric subjects 5 years of age and above and is expected to be
VALN Ratings Summary
VALN Quant Ranking